TY - JOUR
T1 - ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation
AU - Martínez, Haydee
AU - Nagurney, Michelle
AU - Wang, Zi Xuan
AU - Eberhart, Charles G.
AU - Heaphy, Christopher M.
AU - Curtis, Mark T.
AU - Rodriguez, Fausto J.
N1 - Funding Information:
This study was supported in part by Lauren's First and Goal, and the Stick it to Brain Tumors Annual Women's Ice Hockey Tournament (F.J.R.), Department of Defense (grant W81XWH-18-1-0496) (F.J.R.), and NIH (grant P30 CA006973) to the Sidney Kimmel Comprehensive Cancer Center (PI: W. Nelson).
Publisher Copyright:
© 2019 American Association of Neuropathologists, Inc. All rights reserved.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Pineal parenchymal tumors are rare neoplasms, ranging from WHO Grade I to IV. There are few studies characterizing the molecular profiles of these tumors. ATRX alterations are strongly associated with the presence of the alternative lengthening of telomeres (ALT) phenotype, and within the central nervous system they tend to occur in subsets of gliomas, including those with IDH, NF1, or histone (H3 K27M or G34) mutations. Here, we identified ATRX frameshift mutations by next generation sequencing associated with corresponding protein loss in 2 cases of pineal parenchymal tumors of intermediate differentiation (PPTID) developing in a 21-year-old woman and a 64-year-old man. In contrast, we identified partial ATRX loss in 1 pineoblastoma, among 14 pineal parenchymal tumors of various grades (6 pineoblastomas, 4 pineocytomas, and 4 PPTID) using tissue microarrays; ALT was absent in these cases. Evaluating the cBioPortal database, an ATRX mutation was identified in one (of 3 total) PPTIDs analyzed. Thus, ATRX mutations associated with protein loss and ALT develop in a small subset of pineal parenchymal tumors and may be limited to those with intermediate differentiation. The clinical significance of these alterations requires further study.
AB - Pineal parenchymal tumors are rare neoplasms, ranging from WHO Grade I to IV. There are few studies characterizing the molecular profiles of these tumors. ATRX alterations are strongly associated with the presence of the alternative lengthening of telomeres (ALT) phenotype, and within the central nervous system they tend to occur in subsets of gliomas, including those with IDH, NF1, or histone (H3 K27M or G34) mutations. Here, we identified ATRX frameshift mutations by next generation sequencing associated with corresponding protein loss in 2 cases of pineal parenchymal tumors of intermediate differentiation (PPTID) developing in a 21-year-old woman and a 64-year-old man. In contrast, we identified partial ATRX loss in 1 pineoblastoma, among 14 pineal parenchymal tumors of various grades (6 pineoblastomas, 4 pineocytomas, and 4 PPTID) using tissue microarrays; ALT was absent in these cases. Evaluating the cBioPortal database, an ATRX mutation was identified in one (of 3 total) PPTIDs analyzed. Thus, ATRX mutations associated with protein loss and ALT develop in a small subset of pineal parenchymal tumors and may be limited to those with intermediate differentiation. The clinical significance of these alterations requires further study.
KW - ATRX
KW - Alternative lengthening of telomeres
KW - Pineal
KW - Pineal parenchymal tumor
KW - Pineal parenchymal tumors of intermediate differentiation (PPTID)
UR - http://www.scopus.com/inward/record.url?scp=85072685190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072685190&partnerID=8YFLogxK
U2 - 10.1093/jnen/nlz050
DO - 10.1093/jnen/nlz050
M3 - Article
C2 - 31225581
AN - SCOPUS:85072685190
SN - 0022-3069
VL - 78
SP - 703
EP - 708
JO - Journal of neuropathology and experimental neurology
JF - Journal of neuropathology and experimental neurology
IS - 8
ER -